Andreia Yuri Yoshigae

Andreia Yuri Yoshigae

Auto-generated profile, based on publicly available information

Andreia Yuri Yoshigae

University of Western Sao Paulo (Unoeste), Presidente Prudente, SP, Brazil

Research Focus & Metrics

Academic Career Length

6Years (2021-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
5 October 2021 in Nutrition and Cancer
Verified
Journal Article
Closed access
WCWilmer Ramírez Carmona
Wilmer Ramírez Carmona
BDBeatriz Díaz-Fabregat
Beatriz Díaz-Fabregat
AYAndreia Yuri Yoshigae
Andreia Yuri Yoshigae
AAAriana Musa de Aquino
Ariana Musa de Aquino
WSWellerson Rodrigo Scarano
Wellerson Rodrigo Scarano
LMLeonardo de Oliveira Mendes
Leonardo de Oliveira Mendes
Although serum ferritin (SF) has been shown in several studies to be a potential cancer biomarker, the results are inconsistent. Herein, a systematic review was performed to investigate the clinical SF levels in different types of tumors in order to verify the role of SF levels as a biomarker for cancer diagnosis. The search was performed using the PubMed/Medline, Cochrane Library, and Scopus databases. Observational studies comparing SF levels between healthy adults and patients with cancer were included. The meta-analysis was carried out according to the inverse variance and random effects model. The standardized mean differences (SMDs) were assessed at 95% confidence intervals (CIs). We found that SF was higher in patients with cancer (SMD 3.07; CI 1.96,4.17), especially for head and neck cancer (SMD 3.88; CI 0.42,7.34), lung cancer (SMD 1.72; CI 0.67,2.78), pancreatic cancer (SMD 6.79; CI 5.66,7.91), and renal cell carcinoma (SMD 1.77; CI 0.48,3.05). Moreover, in the advanced stages (Stages III and IV), ferritin levels were higher than in healthy adults (SMD 4.89; CI 2.72,7.06, and SMD 8.40; CI 6.99,9.82, respectively). SF acts as a biomarker for pancreatic cancer, renal cell carcinoma, lung cancer, and head and neck cancer and is a sensitive biomarker for the detection of advanced stages of tumors.